Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

页码：419 / 427

页数：9

共 50 条

[21] Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome [J].

Fujimaki, K ;

Taguchi, J ;

Fujita, H ;

Hattori, M ;

Yamazaki, E ;

Takahashi, N ;

Fujisawa, S ;

Kanamori, H ;

Maruta, A ;

Ishigatsubo, Y .

BONE MARROW TRANSPLANTATION, 2004, 33 (08) :789-792

[22] Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes [J].

Alatrash, Gheath ;

Saberian, Chantal ;

Bassett, Roland ;

Thall, Peter F. ;

Ledesma, Celina ;

Lu, Yoshimi ;

Daher, May ;

Valdez, Benigno C. ;

Kawedia, Jitesh ;

Popat, Uday ;

Mehta, Rohtesh ;

Oran, Betul ;

Nieto, Yago ;

Olson, Amanda ;

Anderlini, Paolo ;

Marin, David ;

Hosing, Chitra ;

Alousi, Amin M. ;

Shpall, Elizabeth J. ;

Rondon, Gabriela ;

Chen, Julianne ;

Qazilbash, Muzaffar ;

Champlin, Richard E. ;

Kebriaei, Partow .

TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (08) :501.e1-501.e7

[23] Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation [J].

Even-Or, Ehud ;

Kohl, Shahar Altman ;

Zaidman, Irina ;

Stepensky, Polina ;

Molho-Pessach, Vered .

PEDIATRIC TRANSPLANTATION, 2020, 24 (01)

[24] Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study [J].

Liu, Hui ;

Zhai, Xiao ;

Song, Zhaoyang ;

Sun, Jing ;

Xiao, Yang ;

Nie, Danian ;

Zhang, Yu ;

Huang, Fen ;

Zhou, Hongsheng ;

Fan, Zhiping ;

Tu, Sanfang ;

Li, Yonghua ;

Guo, Xutao ;

Yu, Guopan ;

Liu, Qifa .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[25] Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation [J].

Perkins, Janelle B. ;

Kim, Jongphil ;

Anasetti, Claudio ;

Fernandez, Hugo F. ;

Perez, Lia E. ;

Ayala, Ernesto ;

Kharfan-Dabaja, Mohamed A. ;

Tomblyn, Marcie R. ;

Sullivan, Daniel M. ;

Pidala, Joseph A. ;

Field, Teresa L. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (07) :1099-1107

[26] Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study [J].

Hui Liu ;

Xiao Zhai ;

Zhaoyang Song ;

Jing Sun ;

Yang Xiao ;

Danian Nie ;

Yu Zhang ;

Fen Huang ;

Hongsheng Zhou ;

Zhiping Fan ;

Sanfang Tu ;

Yonghua Li ;

Xutao Guo ;

Guopan Yu ;

Qifa Liu .

Journal of Hematology & Oncology, 6

[27] Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome [J].

K Fujimaki ;

J Taguchi ;

H Fujita ;

M Hattori ;

E Yamazaki ;

N Takahashi ;

S Fujisawa ;

H Kanamori ;

A Maruta ;

Y Ishigatsubo .

Bone Marrow Transplantation, 2004, 33 :789-792

[28] Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients [J].

Iravani, M. ;

Evazi, M. R. ;

Mousavi, S. A. ;

Shamshiri, A. R. ;

Tavakoli, M. ;

Ashouri, A. ;

Samiee, S. ;

Chahardovali, B. ;

Alimoghaddam, K. ;

Ghaffari, S. H. ;

Ghavamzadeh, A. .

BONE MARROW TRANSPLANTATION, 2007, 40 (02) :105-110

[29] Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients [J].

M Iravani ;

M R Evazi ;

S A Mousavi ;

A R Shamshiri ;

M Tavakoli ;

A Ashouri ;

S Samiee ;

B Chahardovali ;

K Alimoghaddam ;

S H Ghaffari ;

A Ghavamzadeh .

Bone Marrow Transplantation, 2007, 40 :105-110

[30] Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation [J].

Kimimori Kamijo ;

Yoshimitsu Shimomura ;

Akihito Shinohara ;

Shohei Mizuno ;

Minoru Kanaya ;

Yoshiaki Usui ;

Sung-Won Kim ;

Takahide Ara ;

Ishikazu Mizuno ;

Takuro Kuriyama ;

Hideyuki Nakazawa ;

Ken-ichi Matsuoka ;

Shigeru Kusumoto ;

Nobuo Maseki ;

Masaki Yamaguchi ;

Takashi Ashida ;

Makoto Onizuka ;

Takahiro Fukuda ;

Yoshiko Atsuta ;

Eisei Kondo .

Annals of Hematology, 2023, 102 :651-661

← 1 2 3 4 5 →